SungHyun Kim

9PUBLICATIONS
88CO-AUTHORS
Pharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular medicinePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 12, 2025
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.

Mark G Lebwohl, John Y Koo, Janusz Jaworski

|Apr 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber

|Mar 28, 2025
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.

David M Pariser, Mark G Lebwohl, Janusz Jaworski

|Feb 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.

Mark G Lebwohl, John Y Koo, Janusz Jaworski

|Jan 13, 2025
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.

Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler

|Oct 17, 2024
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.

Miwa Haranaka, Takashi Eto, Takanori Tanaka

Pageof 2

Frequent Collaborators

5 joint publications

YunJu Bae

4 joint publications

Jakub Trefler

2 joint publications

Josef S Smolen

2 joint publications

Gerd Burmester